RxDoctor Payments Data

Shannon Hallman

Adult Health · West Columbia, SCNPI 1528133915

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,428 of the $7,323 with a category attached, or 87.8%. It is spread thinly across 60 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,542, 3.1 times the $817 reported in 2021. Among adult health clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,323in general payments, 2019–2025

Across 274 payments — averaging $26.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$917
  • Incyte Corporation$739
  • Novartis$521
  • Johnson & Johnson$400
  • Merck$370
  • E.r. Squibb & Sons, L.L.C.$355
  • plus $4K from 54 others

What the payments were for

  • Consulting fees$6008%
  • Food & beverage$6,42888%
  • Education$2954%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca12$917
Incyte Corporation19$739
Novartis23$521
Johnson & Johnson15$400
Merck14$370
E.r. Squibb & Sons, L.L.C.18$355
Gilead(2 entities)7$336
Pfizer17$292
Bristol Myers Squibb15$275
Sanofi4$270
Daiichi Sankyo Inc.12$269
AbbVie11$240
Genentech USA, Inc.11$211
Rigel Pharmaceuticals, Inc.4$159
Amgen3$152
Regeneron Healthcare Solutions, Inc.7$150
Eisai Inc.5$109
Lilly USA, LLC4$82
Taiho Oncology, Inc.4$82
Astellas Pharma US Inc4$75
Iovance Biotherapeutics, Inc.2$60
GSK3$59
Takeda Pharmaceuticals U.S.A., Inc.2$56
ADC Therapeutics America, Inc.3$54
Beigene USA, Inc.3$52
Mirati Therapeutics, Inc.3$52
Stemline Therapeutics Inc.2$51
Array Biopharma Inc4$50
Bayer2$48
Jazz Pharmaceuticals Inc.3$47
Beone Medicines USA, Inc.2$39
Sobi, Inc2$39
Acrotech Biopharma Inc.2$38
Puma Biotechnology, Inc.2$38
Pharmacosmos Therapeutics Inc.1$38
Blueprint Medicines Corporation2$38
EMD Serono, Inc.2$34
Legend Biotech USA Inc.1$33
Janssen Scientific Affairs, LLC1$32
Seagen Inc.2$31
Boehringer Ingelheim1$28
Syndax Pharmaceuticals, Inc.1$28
Karyopharm Therapeutics Inc.1$26
Celltrion USA Inc.1$24
Geron Corporation1$22
Morphosys, US Inc.1$22
Genmab U.S., Inc.1$22
AVEO Pharmaceuticals, Inc.1$22
Adaptive Biotechnologies Corporation1$22
Coherus Oncology, Inc.1$21
Cycle Pharmaceuticals Inc1$21
Pharmaessentia USA Corporation1$20
Pharmacyclics LLC, An Abbvie Company1$20
Servier Pharmaceuticals LLC1$20
Sun Pharmaceutical Industries Inc.1$18
Spectrum Pharmaceuticals Inc.1$18
Kyowa Kirin, Inc.1$17
Tempus AI, Inc1$17
Deciphera Pharmaceuticals Inc.1$15
Springworks Therapeutics, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,323 in reported general payments places this provider in the 90th percentile of 292 adult health providers in South Carolina.

See all adult health providers in South Carolina

Medicare billing

Part B allowed, 2024
$98,505
Medicare patients
437
Services billed
4,651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban15$10,739
Hydroxyurea16$376
Prochlorperazine Maleate20$268
Anastrozole16$219
Ondansetron OdtOndansetron11$217
Acyclovir12$182
Gabapentin24$144
Mirtazapine11$109
Letrozole14$108
Ciprofloxacin Hcl15$43

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$292$10,73915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 292 adult health providers in South Carolina.

Other adult health in West Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →